MuSK Antibody

Immunity

Report in 96Hrs

At Home

No Fasting Required

Details

Autoantibody test.

₹7,800₹11,142

30% OFF

MuSK Antibody Test - Comprehensive Medical Information Guide

Why is it done?
- Detects antibodies against muscle-specific kinase (MuSK), a protein involved in neuromuscular transmission and acetylcholine receptor clustering at the neuromuscular junction
- Diagnoses seronegative myasthenia gravis (MG) in patients who test negative for acetylcholine receptor (AChR) antibodies
- Evaluates patients presenting with symptoms of autoimmune myasthenia gravis, including muscle weakness, ptosis, diplopia, and bulbar symptoms
- Performs seronegative MG screening when clinical presentation strongly suggests myasthenia gravis but initial AChR antibody testing is negative
- Typically ordered during initial diagnostic workup in neurology clinic or following negative AChR antibody results in suspected myasthenia gravis patients
- May be used for disease monitoring and assessment of treatment response in MuSK-positive MG patients
Normal Range
- Reference Value: Negative or <0.40 nmol/L (or laboratory-specific cutoff)
- Negative Result: No detectable MuSK antibodies; indicates absence of MuSK-associated myasthenia gravis
- Positive Result: ≥0.40 nmol/L or above laboratory-specific cutoff; indicates presence of MuSK antibodies consistent with MuSK-positive myasthenia gravis
- Borderline/Equivocal Results: Values near the cutoff may require repeat testing or confirmatory methods
- Units of Measurement: nmol/L (nanomoles per liter) or laboratory-specific units; most commonly reported as qualitative positive or negative
- Clinical Interpretation: Normal (negative) results do not rule out myasthenia gravis if clinical suspicion remains high; approximately 40% of MG patients are seronegative for both AChR and MuSK antibodies
Interpretation
- Positive MuSK Antibodies: Strongly indicates MuSK-positive autoimmune myasthenia gravis; typically accounts for 40-50% of seronegative MG cases and approximately 5-10% of all MG cases
- Negative MuSK Antibodies with AChR-Positive: Excludes MuSK-MG; patient has classical AChR-antibody-positive myasthenia gravis
- Negative MuSK and AChR Antibodies: Double-seronegative MG; neurophysiologic studies (repetitive nerve stimulation, single-fiber EMG) and clinical assessment become primary diagnostic tools
- Titer Levels: Quantitative antibody titers may correlate with disease severity; higher titers generally associated with more severe disease, but individual variation exists
- Clinical Phenotype Differences: MuSK-positive MG often presents with bulbar and neck/respiratory muscle involvement; may have more severe fluctuating weakness; sometimes presents with myasthenic crises
- Factors Affecting Results: Immunosuppressive therapy may reduce antibody titers; disease remission possible after treatment; early disease may have lower antibody levels; testing sensitivity approximately 80% in MuSK-MG patients
- Temporal Pattern: Antibody presence typically persistent but levels may fluctuate with disease activity; may remain positive after clinical remission; conversion to seronegative status rare
Associated Organs
- Primary Organ System: Neuromuscular junction and skeletal muscles; autoimmune attack targets MuSK protein at neuromuscular junction, disrupting signal transmission from nerve to muscle
- Primary Condition: Myasthenia gravis, specifically MuSK-positive subtype; autoimmune neuromuscular transmission disorder
- Associated Muscle Groups Affected: Ocular muscles (ptosis, diplopia), bulbar muscles (speech, swallowing difficulty), neck and respiratory muscles; proximal limb weakness may develop
- Related Autoimmune Conditions: May occur with other autoimmune disorders; rare association with Lambert-Eaton myasthenic syndrome; less commonly associated with thymoma than AChR-positive MG
- Potential Complications: Myasthenic crisis with respiratory muscle paralysis requiring mechanical ventilation; aspiration pneumonia from bulbar dysfunction; sudden exacerbations triggered by infections or stress
- Peripheral Nervous System Impact: Pathogenic antibodies block or destroy MuSK, preventing proper clustering of acetylcholine receptors; leads to compromised neuromuscular transmission and muscle weakness
- Systemic Implications: While primarily neuromuscular, may require systemic immunosuppression; affects quality of life, functional capacity, and requires multidisciplinary management
Follow-up Tests
- Neurophysiologic Studies: Repetitive nerve stimulation (RNS) to assess for decremental response indicating neuromuscular junction dysfunction; single-fiber electromyography (SFEMG) for increased jitter and blocking
- Acetylcholine Receptor (AChR) Antibody Testing: If not already performed; to confirm double-seronegative status and characterize antibody profile
- Chest Imaging (CT or MRI): To screen for thymoma or thymic abnormalities; though less common in MuSK-positive MG, thymectomy may be considered in selected cases
- Edrophonium (Tensilon) Testing: Rarely used currently; historically used to confirm neuromuscular junction disorder; now largely replaced by neurophysiologic testing
- Thyroid Function Tests: TSH and thyroid antibodies; assess for autoimmune thyroid disease which may coexist
- Complete Blood Count and Metabolic Panel: Baseline assessment and monitoring during immunosuppressive therapy; assess for treatment-related cytopenias or organ dysfunction
- Liver and Renal Function Tests: For baseline and ongoing monitoring if using immunosuppressive agents like azathioprine, mycophenolate, or corticosteroids
- Pulmonary Function Tests: If respiratory involvement suspected; particularly important in MuSK-MG which may present with bulbar and respiratory symptoms
- Monitoring Frequency: Repeat MuSK antibody testing typically not necessary if positive; may repeat if clinical presentation changes; neurophysiologic testing repeated as needed to assess disease course
- Clinical Assessment Tools: Quantitative myasthenia gravis score (QMG) for objective disease severity assessment; myasthenia gravis composite (MGC) score for treatment response monitoring
Fasting Required?
- Fasting Status: No - fasting is NOT required for MuSK antibody testing
- Meal Restrictions: Patient may eat and drink normally before testing; no dietary modifications needed
- Medication Considerations: Continue all regular medications including myasthenia gravis treatments (pyridostigmine, immunosuppressants); these do not interfere with antibody testing
- Special Instructions: Arrive at laboratory well-rested if possible, as myasthenia gravis symptoms worsen with fatigue; schedule appointment when symptoms typically less severe
- Sample Collection: Blood sample (serum) collected by venipuncture; no special collection tube required; standard serum separator tube acceptable
- Handling and Storage: Sample should be refrigerated if not immediately processed; maintained at 2-8°C; most laboratories can process samples up to one week after collection
- Turnaround Time: Results typically available within 3-7 business days; some reference laboratories may take up to 2 weeks; discuss with laboratory regarding specific timeline
- Patient Preparation Summary: No fasting; continue all medications; wear comfortable clothing for blood draw; consider scheduling at time of day when myasthenia gravis symptoms minimal for comfort during visit

How our test process works!